Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Lbp Am Sa

Lbp Am Sa increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 41.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 212,835 shares of the biopharmaceutical company’s stock after purchasing an additional 61,948 shares during the quarter. Lbp Am Sa’s holdings in Gilead Sciences were worth $19,660,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the stock. Swedbank AB grew its position in shares of Gilead Sciences by 10.2% in the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after purchasing an additional 189,622 shares during the period. Venturi Wealth Management LLC lifted its stake in shares of Gilead Sciences by 60.9% during the third quarter. Venturi Wealth Management LLC now owns 1,493 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 565 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its stake in shares of Gilead Sciences by 49.9% during the third quarter. Nations Financial Group Inc. IA ADV now owns 8,447 shares of the biopharmaceutical company’s stock worth $708,000 after purchasing an additional 2,813 shares in the last quarter. Aptus Capital Advisors LLC lifted its stake in shares of Gilead Sciences by 3.9% in the third quarter. Aptus Capital Advisors LLC now owns 8,263 shares of the biopharmaceutical company’s stock worth $693,000 after acquiring an additional 309 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its stake in shares of Gilead Sciences by 0.5% in the third quarter. Oppenheimer Asset Management Inc. now owns 184,172 shares of the biopharmaceutical company’s stock worth $15,441,000 after acquiring an additional 948 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $113.35 on Friday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company’s 50-day moving average is $101.42 and its 200 day moving average is $92.47. The company has a market capitalization of $141.16 billion, a price-to-earnings ratio of 306.35, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.79%. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Analyst Upgrades and Downgrades

GILD has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Citigroup assumed coverage on Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price for the company. Oppenheimer increased their price objective on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 4th. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Finally, Morgan Stanley increased their target price on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a report on Tuesday. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.52.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the sale, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 311,285 shares of company stock worth $31,284,910. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.